| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司是一家具有自主创新研发实力，专注于病毒及免疫性疾病领域，集创新药物研发、生产、销售于一体的高科技生物医药公司，入选北京市“专精特新”小巨人企业、北京市生物医药产业跨越发展(G20)工程企业。公司于2021年2月8日正式在上海证券交易所科创板挂牌上市。 研发实力 经过十余年不断积累，公司构建了以中和抗体发现技术、重组蛋白和抗体产业化技术等为核心的生物医药技术平台，组建了包括新药发现、CMC研究、临床前研究和临床研究的研发队伍，打造了具备药物全产业链开发能力的研发体系。近年来，公司共承担了7项国家“十二五”、“十三五”国家科技重大专项，获得了2个创新药注册批件和3个创新药临床批件；截至2022年末，公司累计获得50项境内外发明专利，为“北京市专利示范单位”。 当前，凯因科技重点聚焦以创新药为核心的乙肝功能性治愈药物组合研发，布局了涵盖重组蛋白、单克隆抗体、小分子药物、siRNA等多种药物类型在内的产品管线；同时，布局免疫性疾病领域提高预防保护率与临床治愈率的创新药物管线，不断提升病毒及免疫性疾病的临床治愈率，增强公司核心竞争力。 公司现有多款成熟的商业化品种，包括国内唯一一款干扰素泡腾片剂型的金舒喜?（人干扰素α2b阴道泡腾片）、凯因益生?(人干扰素α2b注射液)、凯因甘乐?/甘毓?（复方甘草酸苷系列产品）等，市场份额均位居前列；针对罕见病IPF（特发性肺纤维化）的药物安博司?（吡非尼酮片），与国内医药商业公司合作推广，以便其更高效地触达市场、惠及更多IPF患者。公司1类新药凯力唯?（盐酸可洛派韦胶囊）于2020年1季度获批上市，同年进入国家医保目录，是第一个被纳入国家医保目录的国产直接抗病毒药物，使公司成为国内第一家成功开发出丙肝高治愈率泛基因型全口服系列药物的企业，打破了进口垄断。 前景展望 凯因科技将秉承“创新·让生命更美好”的使命，坚持创新引领，致力成为病毒及免疫疾病领域先锋力量，护佑生命健康。 | ||||||||||||||||||||||||
| Main Business | 病毒及免疫性疾病领域创新药物的研发、生产、销售。 | ||||||||||||||||||||||||
| Legal Representative | 周德胜 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 赫崇飞 | ||||||||||||||||||||||||
| Solicitors | 广东信达律师事务所 | ||||||||||||||||||||||||
| Auditors | 中汇会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 010-67892271 | ||||||||||||||||||||||||
| Fax No | 010-67892271 | ||||||||||||||||||||||||
| Website | www.kawin.com.cn | ||||||||||||||||||||||||
| ir@kawin.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 08/02/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.700 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.250 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 10.260 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.833B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |